Compares immune-suppressing medicines for ocular myasthenia gravis without thymoma
Studies outcomes of different medicines in adults with new eye-muscle myasthenia gravis.
Plain-language title generated from the registry record
Registry title: TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
Key facts
- Where
- Xi'an, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04182984, who can take part
Where in China
- Tangdu HospotalXi'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tang-Du Hospital
- Trial code
- NCT04182984
- Record updated
- 30 January 2026
- Original description
This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).Read full original descriptionShow less
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).
Inclusion: Age >18 years and<75 years; Clinical Diagnosis of MG with supporting evidence:; Patients with ocular muscle type MG who have never received treatment meet one of the diagnoses (1) and (2)-(5): (1) The patient's symptoms involve the extraocular muscles, except for drooping eyelids and diplopia, no other clinical symptoms; (2) unequivocal clinical response to pyridostigmine; (3) positive acetylcholine receptor antibody or musk antibody; (4) decrement of more than 10% in repetitive nerve stimulations study (RNS); (5) the "trembling" of the single fiber electromyography (SFEMG) is broadened with or without blockade; Willingness to sample collection, imaging study and other disease-related examinations and assessments; The results of pregnancy tests for female subjects with fertility during the screening period should be negative and effective contraception was used by the patient and her spouse during the study period; Patients with informed consent; Predicted survival time is longer than 3 years.
Exclusion: History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue; Patients who may have other diseases that may lead to eyelid drooping, peripheral muscle weakness or diplopia; Patients who have been taking glucocorticoids or associated immunosuppressants due to other immune system diseases; Patients who cannot use immunosuppressants due to other chronic diseases; Patients who are unable to cooperate with follow-up and self-assessment due to severe mental illness or cognitive impairment; Patients who have suffered from severe infections or malignant tumors in the last 1 month and are unable to receive immunosuppressants treatments; Age ≤18 years or ≥75 years; Pregnant women, lactating women and patients with fertility plans during the trial; Patients who are not willing to cooperate with repeated frequency electrical stimulation tests and chest CT examinations; Patients who are not willing to participate in this study; Patients who are unable to sign informed consent; Predicted survival time is shorter than 3 years; Patients who are not suitable to participated in the trial after researchers' assessment.